This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Adentri (oral)
Biogen, Inc.
Drug Names(s): Tonapofylline, BG9928, CVT-124, BG9719, A1 Adenosine Receptor Antagonist
Description: BioMedTracker has separate drug profiles for the oral and intravenous formulations of Adentri. Please also see Adentri (intravenous).
ADENTRI (oral) is an A1 adenosine receptor antagonist.
Deal Structure:
Biogen
In March 1997, Biogen licensed rights to develop adenosine A1 receptor inhibitors from CV Therapeutics. CV Therapeutics' original compound was known as CVT-124 (BG9719).
Astellas
In January 2009, Astellas Pharma announced that it submitted a proposal to the Board of Directors of CV Therapeutics to acquire all outstanding common shares of CV Therapeutics for $16.00 per share in cash.
Gilead
In March 2009, Gilead Sciences and CV Therapeutics announced the signing of a definitive agreement pursuant to which Gilead will acquire CV Therapeutics for $20.00 per share in cash through a tender offer and second step merger. The acquisition was completed in April 2009.
Partners: Gilead Sciences, Inc.
Adentri (oral) News
Pink Sheet Oral Testosterone Battle Looms As Lipocine's Tlando Joins Clarus' Jatenzo In US FDA Review Queue
Additional information available to subscribers only:
- Targets
- Routes
- Catalysts
- Designations
- Events
Request a Free Demo Subscriber Login Search for another drug